# US 2020/0369608 A1 · Processes for preparing pyrrolidine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369608 A1
- Document ID: US20200369608A1
- Status: Published application
- Kind: A1
- Application number: 16/635,346
- Filed: 2018-08-02
- Published: 2020-11-26
- Earliest claimed: 2017-08-02
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: Paul T. Angell; Robert M. Hughes; Berenice Lewandowski; Benjamin J. Littler; William A. Nugent; David Smith; John Studley
- Web page: https://patentgrep.com/patent/US20200369608A1

## CPC

- C07D 207/06: with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 207/263: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Processes for preparing 5,5-dimethyl-3-methylenepyrrolidin-2-one, (S)-3,5,5-trimethylpyrrolidine-2-one, (R)-3,5,5-trimethylpyrrolidine-2-one, (S)-2,4,4-trimethylpyrrolidine, and (R)-2,4,4-trimethylpyrrolidine, and their salt forms are disclosed.

## Claims

### Claim 1

A process for preparing (S)-2,2,4-trimethylpyrrolidine or a salt thereof comprising:
(a) reacting 2,2,6,6-tetramethyl-piperidin-4-one or a salt thereof with chloroform and at least one base;
(b) reacting the products of the reaction in (a) with an acid to produce 5,5-dimethyl-3-methylenepyrrolidin-2-one;
(c) hydrogenating 5,5-dimethyl-3-methylenepyrrolidin-2-one to produce (S)-3,5,5-trimethyl-pyrrolidin-2-one;
(d) reducing (S)-3,5,5-trimethyl-pyrrolidin-2-one to produce (S)-2,2,4-trimethylpyrrolidine; and
(e) optionally treating (S)-2,2,4-trimethylpyrrolidine with acid to produce a salt of (S)-2,2,4-trimethylpyrrolidine.

### Claim 2

A process for preparing (R)-2,2,4-trimethylpyrrolidine or a salt thereof comprising:
(a) reacting 2,2,6,6-tetramethyl-piperidin-4-one or a salt thereof with chloroform and at least one base;
(b) reacting the products of the reaction in (a) with an acid to produce 5,5-dimethyl-3-methylenepyrrolidin-2-one;
(c) hydrogenating 5,5-dimethyl-3-methylenepyrrolidin-2-one to produce (R)-3,5,5-trimethyl-pyrrolidin-2-one;
(d) reducing (R)-3,5,5-trimethyl-pyrrolidin-2-one to produce (R)-2,2,4-trimethylpyrrolidine; and
(e) optionally treating (R)-2,2,4-trimethylpyrrolidine with acid to produce a salt of (R)-2,2,4-trimethylpyrrolidine.

### Claim 3

A process for preparing (S)-3,5,5-trimethylpyrrolidin-2-one comprising:
(a) reacting 2,2,6,6-tetramethyl-piperidin-4-one or a salt thereof with chloroform and at least one base;
(b) reacting the products of the reaction in (a) with an acid to produce 5,5-dimethyl-3-methylenepyrrolidin-2-one; and
(c) hydrogenating 5,5-dimethyl-3-methylenepyrrolidin-2-one to produce (S)-3,5,5-trimethyl-pyrrolidin-2-one.

### Claim 4

A process for preparing (R)-3,5,5-trimethylpyrrolidin-2-one comprising:
(a) reacting 2,2,6,6-tetramethyl-piperidin-4-one or a salt thereof with chloroform and at least one base;
(b) reacting the products of the reaction in (a) with an acid to produce 5,5-dimethyl-3-methylenepyrrolidin-2-one; and
(c) hydrogenating 5,5-dimethyl-3-methylenepyrrolidin-2-one to produce (R)-3,5,5-trimethyl-pyrrolidin-2-one.

### Claim 5

A process for preparing 5,5-dimethyl-3-methylenepyrrolidin-2-one comprising:
(a) reacting 2,2,6,6-tetramethyl-piperidin-4-one or a salt thereof with chloroform and at least one base; and
(b) reacting the products of the reaction in (a) with an acid to produce 5,5-dimethyl-3-methylenepyrrolidin-2-one.

### Claim 6 (depends on 1, 3)

The process according to claim 1 or 3, further comprising treating (S)-2,2,4-trimethylpyrrolidine with HCl to generate (S)-2,2,4-trimethylpyrrolidine hydrochloride.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The process according to any one of claims 1-5, wherein said at least one base is chosen from potassium t-butoxide, potassium hydroxide, and sodium hydroxide.

### Claim 8 (depends on 7)

The process according to claim 7, wherein said at least one base is sodium hydroxide.

### Claim 9 (depends on 1, 2, 3, 4, 5)

The process according to any one of claims 1-5, wherein from 3 to 15 molar equivalents of said at least one base relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one are added for the reaction in (a).

### Claim 10 (depends on 9)

The process according to claim 9, wherein from 5 to 12 molar equivalents of said at least one base are added.

### Claim 11 (depends on 9)

The process according to claim 9, wherein 7.5 molar equivalents of said at least one base are added.

### Claim 12 (depends on 9)

The process according to claim 9, wherein 10 molar equivalents of said at least one base are added.

### Claim 13 (depends on 9)

The process according to claim 9, wherein 8 molar equivalents of sodium hydroxide are added.

### Claim 14 (depends on 1, 2, 3, 4, 5)

The process according to any one of claims 1-5, wherein said at least one base added for the reaction in (a) is in the form of an aqueous solution having a concentration ranging from 20 wt % to 80 wt % relative to the total weight of said aqueous solution.

### Claim 15 (depends on 14)

The process according to claim 14, wherein said at least one base is 20 wt % aqueous NaOH.

### Claim 16 (depends on 14)

The process according to claim 14, wherein said at least one base is 40 wt % aqueous NaOH.

### Claim 17 (depends on 14)

The process according to claim 14, wherein said at least one base is 50 wt % aqueous NaOH.

### Claim 18 (depends on 1, 2, 3, 4, 5)

The process according to any one of claims 1-5, wherein said chloroform is present in an amount ranging from 1 to 4 molar equivalents relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one.

### Claim 19 (depends on 18)

The process according to claim 18, wherein said chloroform is present in an amount ranging from 1.5 to 3.5 molar equivalents relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one.

### Claim 20 (depends on 18)

The process according to claim 18, wherein said chloroform is present in an amount of 1.75 molar equivalents relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The process according to any one of claims 1-20, wherein said 2,2,6,6-tetramethyl-piperidin-4-one or a salt thereof is reacted with chloroform, at least one base, and at least one phase transfer catalyst.

### Claim 22 (depends on 21)

The process according to claim 21, wherein at least one phase transfer catalyst is chosen from tetraalkylammonium salts and crown ethers.

### Claim 23 (depends on 21)

The process according to claim 21, wherein said at least one phase transfer catalyst is chosen from tetraalkylammonium salts.

### Claim 24 (depends on 21)

The process according to claim 21, wherein said at least one phase transfer catalyst is chosen from tetraalkylammonium halides.

### Claim 25 (depends on 21)

The process according to claim 21, wherein said at least one phase transfer catalyst is chosen from tributylmethylammonium chloride, tributylmethylammonium bromide, tetrabutylammonium bromide (TBAB), tetrabutylammonium chloride (TBAC), tetrabutylammonium iodide (TBAI), tetrabutylammonium hydroxide (TBAH), benzyltrimethylammonium chloride, tetraoctylammonium bromide (TAOB), tetraoctylammonium chloride (TAOC), tetraoctylammonium iodide (TAOI), trioctylmethylammonium chloride, and trioctylmethylammonium bromide.

### Claim 26 (depends on 21, 22, 23, 24, 25)

The process according to any one of claims 21-25, wherein from 0.01 molar equivalents to 0.2 molar equivalents of said at least one phase transfer catalyst relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one is added to the reaction in (a).

### Claim 27 (depends on 26)

The process according to claim 26, wherein from 0.02 molar equivalents to 0.1 molar equivalents of said at least one phase transfer catalyst relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one is added.

### Claim 28 (depends on 26)

The process according to claim 26, wherein from 0.03 molar equivalents to 0.06 molar equivalents of said at least one phase transfer catalyst relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one is added.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The process according to any one of claims 1-28, wherein said acid of the reaction in (b) is chosen from aqueous solutions of protic acids.

### Claim 30 (depends on 29)

The process according to claim 29, wherein said protic acids are chosen from hydrochloric acid, methane sulfonic acid, triflic acid, and sulfuric acid.

### Claim 31 (depends on 29)

The process according to claim 29, wherein the concentration of said aqueous solutions of protic acids range from 1M to 18M.

### Claim 32 (depends on 31)

The process according to claim 31, wherein the concentration of said aqueous solutions of protic acids range from 2M to 10M.

### Claim 33 (depends on 32)

The process according to claim 32, wherein said acid of the reaction in (b) is chosen from HCl having a concentration ranging from 2M to 3M.

### Claim 34 (depends on 33)

The process according to claim 33, wherein said acid of the reaction in (b) is chosen from 2M HCl.

### Claim 35 (depends on 33)

The process according to claim 33, wherein said acid of the reaction in (b) is chosen from 2.5M HCl.

### Claim 36 (depends on 33)

The process according to claim 33, wherein said acid of the reaction in (b) is chosen from 3M HCl.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The process according to any one of claims 1-36, wherein 0.5 to 10 molar equivalents of said acid relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one are added to the reaction in (b).

### Claim 38 (depends on 37)

The process according to claim 37, wherein 1 to 4 molar equivalents of said acid relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one are added to the reaction in (b).

### Claim 39 (depends on 37)

The process according to claim 37, wherein 1.5 molar equivalents of said acid relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one are added to the reaction in (b).

### Claim 40 (depends on 1, 2, 3, 4, 5)

The process according to any one of claims 1-5, wherein a yield of 5,5-dimethyl-3-methylenepyrrolidin-2-one produced from the reactions in (a) and (b) ranges from 40% to 70% relative to the mole of 2,2,6,6-tetramethylpiperidin-4-one.

### Claim 41 (depends on 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The process according to any one of claims 1-4 or 6-40, wherein said hydrogenating reaction in (c) comprises reacting 5,5-dimethyl-3-methylenepyrrolidin-2-one with at least one catalyst and hydrogen gas to produce (S)-3,5,5-trimethyl-pyrrolidin-2-one.

### Claim 42 (depends on 41)

The process according to claim 41, wherein said catalyst is chosen from ruthenium hydrogenation catalysts, rhodium hydrogenation catalysts, and iridium hydrogenation catalysts.

### Claim 43 (depends on 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The process according to any one of claims 1 or 6-42, wherein said reducing reaction in (d) comprises reacting (S)-3,5,5-trimethyl-pyrrolidin-2-one with a hydride to produce (S)-2,2,4-trimethylpyrrolidine.

### Claim 44 (depends on 41)

The process according to claim 41, wherein said reducing reaction comprises reacting 1-2 molar equivalents of hydride relative to the mole of (S)-3,5,5-trimethyl-pyrrolidin-2-one.

### Claim 45 (depends on 41)

The process according to claim 41, wherein said hydride is chosen from lithium aluminum hydride, sodium bis(2-methoxyethoxy)aluminumhydride, and borane.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The process according to any one of claims 1-45, wherein 2,2,6,6-tetramethyl-piperidin-4-one or a salt thereof is reacted with chloroform, at least one base, and at least one solvent.

### Claim 47 (depends on 46)

The process according to claim 46, wherein the at least one solvent is chosen from organic solvents.

### Claim 48 (depends on 47)

The process according to claim 47, wherein the at least one solvent is chosen from dichloromethane, heptane, chloroform, trifluorotoluene, tetrahydrofuran (THF), and N-methylpyrrolidone (NMP).
